Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Akorn and Azad Ink Glaucoma Deal

  • Akorn signed a definitive agreement with Azad Pharma related to the development and supply of three candidates for the treatment of glaucoma. The companies report that the products, Latanoprost, Bimatoprost, and Travoprost, have a total U.S. market-size of $870 million, according to 2006 IMS data. 

    The drug products are expected to be manufactured by Taejoon Pharmaceutical.  Taejoon and Azad will complete the regulatory dossiers and upon ANDA approval, will manufacture and supply the products to Akorn in a blow-fill seal container closure system. 

    Akorn will be responsible for the regulatory filings of the ANDA's and will own  them. As part of this Agreement, Akorn will have exclusive marketing and distribution rights for the three drug products in the U.S. and Canada.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »